Inflammatory manifestations of HTLV-1 and their therapeutic options

References

• Viruses. ICoTo. HTLV. International Committee on Taxonomy of Viruses. 1991
   Google Scholar
• Manns A, Hisada M, La Grenade L. Human T-lymphotropic virus type I infection. Lancet 1999;353(9168):1951-8
   PubMed Web of Science ®Google Scholar
• Hewitt PE, Davison K, Howell DR, Taylor GP. Human T-lymphotropic virus lookback in NHS Blood and Transplant (England) reveals the efficacy of leukoreduction. Transfusion 2013;53(10):2168-75
   PubMed Web of Science ®Google Scholar
• Okochi K, Sato H. Transmission of adult T-cell leukemia virus (HTLV-I) through blood transfusion and its prevention. AIDS Res 1986;2(Suppl 1):S157-61
   PubMedGoogle Scholar
• Manns A, Wilks RJ, Murphy EL, et al. A prospective study of transmission by transfusion of HTLV-I and risk factors associated with seroconversion. Int J Cancer 1992;51(6):886-91
   PubMed Web of Science ®Google Scholar
• Ando Y, Nakano S, Saito K, et al. Transmission of adult T-cell leukemia retrovirus (HTLV-I) from mother to child: comparison of bottle- with breast-fed babies. Jpn J Cancer Res 1987;78(4):322-4
   PubMedGoogle Scholar
• Bittencourt AL. Vertical transmission of HTLV-I/II: a review. Rev Inst Med Trop Sao Paulo 1998;40(4):245-51
   PubMedGoogle Scholar
• Stuver SO, Tachibana N, Okayama A, et al. Heterosexual transmission of human T cell leukemia/lymphoma virus type I among married couples in southwestern Japan: an initial report from the Miyazaki Cohort Study. J Infect Dis 1993;167(1):57-65
   PubMed Web of Science ®Google Scholar
• Olaleye DO, Bernstein L, Sheng Z, et al. Type-specific immune response to human T cell lymphotropic virus (HTLV) type I and type II infections in Nigeria. Am J Trop Med Hyg 1994;50(4):479-86
   PubMed Web of Science ®Google Scholar
• Kajiyama W, Kashiwagi S, Ikematsu H, et al. Intrafamilial transmission of adult T cell leukemia virus. J Infect Dis 1986;154(5):851-7
   PubMed Web of Science ®Google Scholar
• Larsen O, Andersson S, da Silva Z, et al. Prevalences of HTLV-1 infection and associated risk determinants in an urban population in Guinea-Bissau, West Africa. J Acquir Immune Defic Syndr 2000;25(2):157-63
   PubMed Web of Science ®Google Scholar
• Gotuzzo E, Sanchez J, Escamilla J, et al. Human T cell lymphotropic virus type I infection among female sex workers in Peru. J Infect Dis 1994;169(4):754-9
   PubMed Web of Science ®Google Scholar
• Murphy EL, Figueroa JP, Gibbs WN, et al. Sexual transmission of human T-lymphotropic virus type I (HTLV-I). Ann Intern Med 1989;111(7):555-60
   PubMed Web of Science ®Google Scholar
• Richardson JH, Hollsberg P, Windhagen A, et al. Variable immortalizing potential and frequent virus latency in blood-derived T-cell clones infected with human T-cell leukemia virus type I. Blood 1997;89(9):3303-14
   PubMed Web of Science ®Google Scholar
• Fan N, Gavalchin J, Paul B, et al. Infection of peripheral blood mononuclear cells and cell lines by cell-free human T-cell lymphoma/leukemia virus type I. J Clin Microbiol 1992;30(4):905-10
   PubMed Web of Science ®Google Scholar
• Popovic M, Sarin PS, Robert-Gurroff M, et al. Isolation and transmission of human retrovirus (human t-cell leukemia virus). Science 1983;219(4586):856-9
   PubMed Web of Science ®Google Scholar
• Pais-Correia AM, Sachse M, Guadagnini S, et al. Biofilm-like extracellular viral assemblies mediate HTLV-1 cell-to-cell transmission at virological synapses. Nat Med 2010;16(1):83-9
   PubMed Web of Science ®Google Scholar
• Igakura T, Stinchcombe JC, Goon PK, et al. Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science 2003;299(5613):1713-16
   PubMed Web of Science ®Google Scholar
• de The G, Bomford R. An HTLV-I vaccine: why, how, for whom? AIDS Res Hum Retroviruses 1993;9(5):381-6
   PubMed Web of Science ®Google Scholar
• Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol 2012;3:388
   PubMed Web of Science ®Google Scholar
• Hlela C, Shepperd S, Khumalo NP, Taylor GP. The prevalence of human T-cell lymphotropic virus type 1 in the general population is unknown. AIDS Rev 2009;11(4):205-14
   PubMed Web of Science ®Google Scholar
• Yamaguchi K. Human T-lymphotropic virus type I in Japan. Lancet 1994;343(8891):213-16
   PubMed Web of Science ®Google Scholar
• Mueller N, Okayama A, Stuver S, Tachibana N. Findings from the Miyazaki Cohort Study. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13(Suppl 1):S2-7
   Google Scholar
• Murphy EL, Figueroa JP, Gibbs WN, et al. Human T-lymphotropic virus type I (HTLV-I) seroprevalence in Jamaica. I. Demographic determinants. Am J Epidemiol 1991;133(11):1114-24
   PubMed Web of Science ®Google Scholar
• Sarkodie F, Adarkwa M, Adu-Sarkodie Y, et al. Screening for viral markers in volunteer and replacement blood donors in West Africa. Vox Sang 2001;80(3):142-7
   PubMed Web of Science ®Google Scholar
• Catalan-Soares B, Carneiro-Proietti AB, Proietti FA. Heterogeneous geographic distribution of human T-cell lymphotropic viruses I and II (HTLV-I/II): serological screening prevalence rates in blood donors from large urban areas in Brazil. Cad Saude Publica 2005;21(3):926-31
   PubMedGoogle Scholar
• Carles G, Tortevoye P, Tuppin P, et al. [HTLV1 infection and pregnancy]. J Gynecol Obstet Biol Reprod (Paris) 2004;33(1 Pt 1):14-20
   PubMedGoogle Scholar
• Laperche S, Worms B, Pillonel J. Blood safety strategies for human T-cell lymphotropic virus in Europe. Vox Sang 2009;96(2):104-10
   PubMed Web of Science ®Google Scholar
• Paun L, Ispas O, Del Mistro A, Chieco-Bianchi L. HTLV-I in Romania. Eur J Haematol 1994;52(2):117-18
   PubMed Web of Science ®Google Scholar
• Rafatpanah H, Hedayati-Moghaddam MR, Fathimoghadam F, et al. High prevalence of HTLV-I infection in Mashhad, Northeast Iran: a population-based seroepidemiology survey. J Clin Virol 2011;52(3):172-6
   PubMed Web of Science ®Google Scholar
• Doherty RR. HTLV-I in Australia and Oceania: long-term resident or recent immigrant? Med J Aust 1996;164(2):84-6
   PubMed Web of Science ®Google Scholar
• Taylor GP, Bodeus M, Courtois F, et al. The seroepidemiology of human T-lymphotropic viruses: types I and II in Europe: a prospective study of pregnant women. J Acquir Immune Defic Syndr 2005;38(1):104-9
   PubMed Web of Science ®Google Scholar
• Poiesz BJ, Papsidero LD, Ehrlich G, et al. Prevalence of HTLV-I-associated T-cell lymphoma. Am J Hematol 2001;66(1):32-8
   PubMed Web of Science ®Google Scholar
• Chang YB, Kaidarova Z, Hindes D, et al. Seroprevalence and demographic determinants of human T-lymphotropic virus type 1 and 2 infections among first-time blood donors–United States, 2000-2009. J Infect Dis 2014;209(4):523-31
   PubMed Web of Science ®Google Scholar
• CDC. HTLV I/II Antibody Testing. 2002. Available from: www.n.cdc.gov/mpep/htlv.aspx [Last] [accessed 26 August 2014]
   Google Scholar
• Chen YM, Gomez-Lucia E, Okayama A, et al. Antibody profile of early HTLV-I infection. Lancet 1990;336(8725):1214-16
   PubMed Web of Science ®Google Scholar
• Chen YM, Lee TH, Wiktor SZ, et al. Type-specific antigens for serological discrimination of HTLV-I and HTLV-II infection. Lancet 1990;336(8724):1153-5
   PubMed Web of Science ®Google Scholar
• Nagai M, Usuku K, Matsumoto W, et al. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol 1998;4(6):586-93
   PubMed Web of Science ®Google Scholar
• Tosswill JH, Taylor GP, Clewley JP, Weber JN. Quantification of proviral DNA load in human T-cell leukaemia virus type I infections. J Virol Methods 1998;75(1):21-6
   PubMed Web of Science ®Google Scholar
• Cook LB, Rowan AG, Melamed A, et al. HTLV-1-infected T cells contain a single integrated provirus in natural infection. Blood 2012;120(17):3488-90
   PubMed Web of Science ®Google Scholar
• Martin F, Fedina A, Youshya S, Taylor GP. A 15-year prospective longitudinal study of disease progression in patients with HTLV-1 associated myelopathy in the UK. J Neurol Neurosurg Psychiatry 2010;81(12):1336-40
   PubMed Web of Science ®Google Scholar
• Duggan DB, Ehrlich GD, Davey FP, et al. HTLV-I-induced lymphoma mimicking Hodgkin’s disease. Diagnosis by polymerase chain reaction amplification of specific HTLV-I sequences in tumor DNA. Blood 1988;71(4):1027-32
   PubMed Web of Science ®Google Scholar
• Koga Y, Iwanaga M, Soda M, et al. Trends in HTLV-1 prevalence and incidence of adult T-cell leukemia/lymphoma in Nagasaki. Japan. J Med Virol 2010;82(4):668-74
   PubMed Web of Science ®Google Scholar
• Kondo T, Kono H, Miyamoto N, et al. Age- and sex-specific cumulative rate and risk of ATLL for HTLV-I carriers. Int J Cancer 1989;43(6):1061-4
   PubMed Web of Science ®Google Scholar
• Kaplan JE, Osame M, Kubota H, et al. The risk of development of HTLV-I-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I. J Acquir Immune Defic Syndr 1990;3(11):1096-101
   PubMed Web of Science ®Google Scholar
• Maloney EM, Cleghorn FR, Morgan OS, et al. Incidence of HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Jamaica and Trinidad. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17(2):167-70
   PubMedGoogle Scholar
• Pinheiro SR, Martins-Filho OA, Ribas JG, et al. Immunologic markers, uveitis, and keratoconjunctivitis sicca associated with human T-cell lymphotropic virus type 1. Am J Ophthalmol 2006;142(5):811-15
   PubMed Web of Science ®Google Scholar
• Mochizuki M, Yamaguchi K, Takatsuki K, et al. HTLV-I and uveitis. Lancet 1992;339(8801):1110
   PubMed Web of Science ®Google Scholar
• LaGrenade L, Hanchard B, Fletcher V, et al. Infective dermatitis of Jamaican children: a marker for HTLV-I infection. Lancet 1990;336(8727):1345-7
   PubMed Web of Science ®Google Scholar
• Sugimoto M, Nakashima H, Watanabe S, et al. T-lymphocyte alveolitis in HTLV-I-associated myelopathy. Lancet 1987;2(8569):1220
   PubMed Web of Science ®Google Scholar
• Guerin B, Arfi S, Numeric P, et al. Polyarthritis in HTLV-1-infected patients. A review of 17 cases. Rev Rhum Engl Ed 1995;62(1):21-8
   PubMedGoogle Scholar
• Deguchi HE, Amemiya T. Two cases of uveitis with tubulointerstitial nephritis in HTLV-1 carriers. Jpn J Ophthalmol 2003;47(4):372-8
   PubMed Web of Science ®Google Scholar
• Smadja D, Bellance R, Cabre P, et al. Clinical characteristics of HTLV-1 associated dermato-polymyositis. Seven cases from Martinique. Acta Neurol Scand 1995;92(3):206-12
   PubMed Web of Science ®Google Scholar
• Bangham CR, Osame M. Cellular immune response to HTLV-1. Oncogene 2005;24(39):6035-46
   PubMed Web of Science ®Google Scholar
• Vine AM, Witkover AD, Lloyd AL, et al. Polygenic control of human T lymphotropic virus type I (HTLV-I) provirus load and the risk of HTLV-I-associated myelopathy/tropical spastic paraparesis. J Infect Dis 2002;186(7):932-9
   PubMed Web of Science ®Google Scholar
• Nose H, Saito M, Usuku K, et al. Clinical symptoms and the odds of human T-cell lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in healthy virus carriers: application of best-fit logistic regression equation based on host genotype, age, and provirus load. J Neurovirol 2006;12(3):171-7
   PubMed Web of Science ®Google Scholar
• Hisada M, Stuver SO, Okayama A, et al. Persistent paradox of natural history of human T lymphotropic virus type I: parallel analyses of Japanese and Jamaican carriers. J Infect Dis 2004;190(9):1605-9
   PubMed Web of Science ®Google Scholar
• Franzoi AC, Araujo AQ. Disability profile of patients with HTLV-I-associated myelopathy/tropical spastic paraparesis using the Functional Independence Measure (FIM). Spinal Cord 2005;43(4):236-40
   PubMed Web of Science ®Google Scholar
• Merle H, Cabre P, Olindo S, et al. Ocular lesions in 200 patients infected by the human T-cell lymphotropic virus type 1 in martinique (French West Indies). Am J Ophthalmol 2002;134(2):190-5
   PubMed Web of Science ®Google Scholar
• Olindo S, Lezin A, Cabre P, et al. HTLV-1 proviral load in peripheral blood mononuclear cells quantified in 100 HAM/TSP patients: a marker of disease progression. J Neurol Sci 2005;237(1-2):53-9
   PubMed Web of Science ®Google Scholar
• Ono A, Mochizuki M, Yamaguchi K, et al. Increased number of circulating HTLV-1 infected cells in peripheral blood mononuclear cells of HTLV-1 uveitis patients: a quantitative polymerase chain reaction study. Br J Ophthalmol 1995;79(3):270-6
   PubMed Web of Science ®Google Scholar
• Takenouchi N, Yamano Y, Usuku K, et al. Usefulness of proviral load measurement for monitoring of disease activity in individual patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis. J Neurovirol 2003;9(1):29-35
   PubMed Web of Science ®Google Scholar
• Taylor GP, Tosswill JH, Matutes E, et al. Prospective study of HTLV-I infection in an initially asymptomatic cohort. J Acquir Immune Defic Syndr 1999;22(1):92-100
   PubMed Web of Science ®Google Scholar
• Nagai M, Yamano Y, Brennan MB, et al. Increased HTLV-I proviral load and preferential expansion of HTLV-I Tax-specific CD8+ T cells in cerebrospinal fluid from patients with HAM/TSP. Ann Neurol 2001;50(6):807-12
   PubMed Web of Science ®Google Scholar
• Cruickshank JK, Rudge P, Dalgleish AG, et al. Tropical spastic paraparesis and human T cell lymphotropic virus type 1 in the United Kingdom. Brain 1989;112(Pt 4):1057-90
   PubMed Web of Science ®Google Scholar
• Puccioni-Sohler M, Gasparetto E, Cabral-Castro MJ, et al. HAM/TSP: association between white matter lesions on magnetic resonance imaging, clinical and cerebrospinal fluid findings. Arq Neuropsiquiatr 2012;70(4):246-51
   PubMed Web of Science ®Google Scholar
• Asquith B, Mosley AJ, Heaps A, et al. Quantification of the virus-host interaction in human T lymphotropic virus I infection. Retrovirology 2005;2:75
   PubMed Web of Science ®Google Scholar
• Hilburn S, Rowan A, Demontis MA, et al. In vivo expression of human T-lymphotropic virus type 1 basic leucine-zipper protein generates specific CD8+ and CD4+ T-lymphocyte responses that correlate with clinical outcome. J Infect Dis 2011;203(4):529-36
   PubMed Web of Science ®Google Scholar
• Saito M, Matsuzaki T, Satou Y, et al. In vivo expression of the HBZ gene of HTLV-1 correlates with proviral load, inflammatory markers and disease severity in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP). Retrovirology 2009;6:19
   PubMed Web of Science ®Google Scholar
• Macnamara A, Rowan A, Hilburn S, et al. HLA class I binding of HBZ determines outcome in HTLV-1 infection. PLoS Pathog 2010;6(9):e1001117
   PubMed Web of Science ®Google Scholar
• Goncalves DU, Proietti FA, Barbosa-Stancioli EF, et al. HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) inflammatory network. Inflamm Allergy Drug Targets 2008;7(2):98-107
   PubMedGoogle Scholar
• Guerreiro JB, Santos SB, Morgan DJ, et al. Levels of serum chemokines discriminate clinical myelopathy associated with human T lymphotropic virus type 1 (HTLV-1)/tropical spastic paraparesis (HAM/TSP) disease from HTLV-1 carrier state. Clin Exp Immunol 2006;145(2):296-301
   PubMed Web of Science ®Google Scholar
• Sagawa K, Mochizuki M, Masuoka K, et al. Immunopathological mechanisms of human T cell lymphotropic virus type 1 (HTLV-I) uveitis. Detection of HTLV-I-infected T cells in the eye and their constitutive cytokine production. J Clin Invest 1995;95(2):852-8
   PubMed Web of Science ®Google Scholar
• Sato T, Coler-Reilly A, Utsunomiya A, et al. CSF CXCL10, CXCL9, and neopterin as candidate prognostic biomarkers for HTLV-1-associated myelopathy/tropical spastic paraparesis. PLoS Negl Trop Dis 2013;7(10):e2479
   PubMed Web of Science ®Google Scholar
• Saito M, Bangham CR. Immunopathogenesis of human T-cell leukemia virus type-1-associated myelopathy/tropical spastic paraparesis: recent perspectives. Leukemia Res Treat 2012;2012:259045
   PubMedGoogle Scholar
• Gillet NA, Malani N, Melamed A, et al. The host genomic environment of the provirus determines the abundance of HTLV-1-infected T-cell clones. Blood 2011;117(11):3113-22
   PubMed Web of Science ®Google Scholar
• Meekings KN, Leipzig J, Bushman FD, et al.1 integration into transcriptionally active genomic regions is associated with proviral expression and with HAM/TSP. PLoS Pathog 2008;4(3):e1000027
   Web of Science ®Google Scholar
• Gillet NA, Cook L, Laydon DJ, et al. Strongyloidiasis and infective dermatitis alter human T lymphotropic virus-1 clonality in vivo. PLoS Pathog 2013;9(4):e1003263
   PubMed Web of Science ®Google Scholar
• Jeffery KJ, Siddiqui AA, Bunce M, et al. The influence of HLA class I alleles and heterozygosity on the outcome of human T cell lymphotropic virus type I infection. J Immunol 2000;165(12):7278-84
   PubMed Web of Science ®Google Scholar
• Jeffery KJ, Usuku K, Hall SE, et al. HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. P Natl Acad Sci USA 1999;96(7):3848-53
   PubMed Web of Science ®Google Scholar
• Furukawa Y, Yamashita M, Usuku K, et al. Phylogenetic subgroups of human T cell lymphotropic virus (HTLV) type I in the tax gene and their association with different risks for HTLV-I-associated myelopathy/tropical spastic paraparesis. J Infect Dis 2000;182(5):1343-9
   PubMed Web of Science ®Google Scholar
• Sabouri AH, Saito M, Usuku K, et al. Differences in viral and host genetic risk factors for development of human T-cell lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis between Iranian and Japanese HTLV-1-infected individuals. J Gen Virol 2005;86(Pt 3):773-81
   PubMed Web of Science ®Google Scholar
• Vine AM, Heaps AG, Kaftantzi L, et al. The role of CTLs in persistent viral infection: cytolytic gene expression in CD8+ lymphocytes distinguishes between individuals with a high or low proviral load of human T cell lymphotropic virus type 1. J Immunol 2004;173(8):5121-9
   PubMed Web of Science ®Google Scholar
• Cruikshank EK. A neuropathic syndrome of uncertain origin: review of 100 cases. West Indian Med J 1956;5:147-58
   PubMedGoogle Scholar
• Strachan H. Malarial multiple peripheral neuritis. Sajou’s Ann Univ Med Sci 1888;1:139-41
   Google Scholar
• Gessain A, Barin F, Vernant JC, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985;2(8452):407-10
   PubMed Web of Science ®Google Scholar
• Osame M, Usuku K, Izumo S, et al. HTLV-I associated myelopathy, a new clinical entity. Lancet 1986;1(8488):1031-2
   PubMed Web of Science ®Google Scholar
• Birmann BM, Breen EC, Stuver S, et al. Population differences in immune marker profiles associated with human T-lymphotropic virus type I infection in Japan and Jamaica. Int J Cancer 2009;124(3):614-21
   PubMed Web of Science ®Google Scholar
• Cruickshank JK, Rudge P, Dalgleish AG, et al. Tropical spastic paraparesis and human T cell lymphotropic virus type 1 in the United Kingdom. Brain 1989;112(Pt 4):1057-90
   PubMed Web of Science ®Google Scholar
• Nakagawa M, Izumo S, Ijichi S, et al. HTLV-I-associated myelopathy: analysis of 213 patients based on clinical features and laboratory findings. J Neurovirol 1995;1(1):50-61
   PubMed Web of Science ®Google Scholar
• Olindo S, Cabre P, Lezin A, et al. Natural history of human T-lymphotropic virus 1-associated myelopathy: a 14-year follow-up study. Arch Neurol 2006;63(11):1560-6
   PubMedGoogle Scholar
• Gotuzzo E, Cabrera J, Deza L, et al. Clinical characteristics of patients in Peru with human T cell lymphotropic virus type 1-associated tropical spastic paraparesis. Clin Infect Dis 2004;39(7):939-44
   PubMed Web of Science ®Google Scholar
• Araujo AQ, Leite AC, Dultra SV, Andrada-Serpa MJ. Progression of neurological disability in HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). J Neurol Sci 1995;129(2):147-51
   PubMed Web of Science ®Google Scholar
• Matsuzaki T, Nakagawa M, Nagai M, et al. HTLV-I proviral load correlates with progression of motor disability in HAM/TSP: analysis of 239 HAM/TSP patients including 64 patients followed up for 10 years. J Neurovirol 2001;7(3):228-34
   PubMed Web of Science ®Google Scholar
• Montgomery RD, Cruickshank EK, Robertson WB, McMenemey WH. Clinical and Pathological Observations on Jamaican Neuropathy; a Report on 206 Cases. Brain 1964;87:425-62
   PubMed Web of Science ®Google Scholar
• Aye MM, Matsuoka E, Moritoyo T, et al. Histopathological analysis of four autopsy cases of HTLV-I-associated myelopathy/tropical spastic paraparesis: inflammatory changes occur simultaneously in the entire central nervous system. Acta Neuropathol 2000;100(3):245-52
   PubMed Web of Science ®Google Scholar
• Iwasaki Y, Ohara Y, Kobayashi I, Akizuki S. Infiltration of helper/inducer T lymphocytes heralds central nervous system damage in human T-cell leukemia virus infection. Am J Pathol 1992;140(5):1003-8
   PubMed Web of Science ®Google Scholar
• Morgan DJ, Caskey MF, Abbehusen C, et al. Brain magnetic resonance imaging white matter lesions are frequent in HTLV-I carriers and do not discriminate from HAM/TSP. AIDS Res Hum Retroviruses 2007;23(12):1499-504
   PubMed Web of Science ®Google Scholar
• Griffith C, Bagnato F, Gupta S, et al. Brain volume measurements in patients with human T-cell lymphotropic virus-1-associated tropical spastic paraparesis. J Neurovirol 2006;12(5):349-55
   PubMed Web of Science ®Google Scholar
• Evangelou IE, Massoud R, Jacobson S. HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis: semiautomatic quantification of spinal cord atrophy from 3-dimensional MR images. J Neuroimaging 2014;24(1):74-8
   PubMed Web of Science ®Google Scholar
• Howard AK, Li DK, Oger J. MRI contributes to the differentiation between MS and HTLV-I associated myelopathy in British Columbian coastal natives. Can J Neurol Sci 2003;30(1):41-8
   PubMed Web of Science ®Google Scholar
• Afonso PV, Ozden S, Cumont MC, et al. Alteration of blood-brain barrier integrity by retroviral infection. PLoS Pathog 2008;4(11):e1000205
   Web of Science ®Google Scholar
• De Castro-Costa CM, Araujo AQ, Barreto MM, et al. Proposal for diagnostic criteria of tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM). AIDS Res Hum Retroviruses 2006;22(10):931-5
   PubMed Web of Science ®Google Scholar
• Imamura A. [Studies on neurogenic bladder due to human T-lymphotropic virus type-I associated myelopathy (HAM)]. Nihon Hinyokika Gakkai Zasshi 1994;85(7):1106-15
   PubMedGoogle Scholar
• Okada F, Ando Y, Yoshitake S, et al. Pulmonary CT findings in 320 carriers of human T-lymphotropic virus type 1. Radiology 2006;240(2):559-64
   PubMed Web of Science ®Google Scholar
• Littleton ET, Man WD, Holton JL, et al. Human T cell leukaemia virus type I associated neuromuscular disease causing respiratory failure. J Neurol Neurosurg Psychiatry 2002;72(5):650-2
   PubMed Web of Science ®Google Scholar
• Marcos LA, Terashima A, Dupont HL, Gotuzzo E. Strongyloides hyperinfection syndrome: an emerging global infectious disease. Trans R Soc Trop Med Hyg 2008;102(4):314-18
   PubMed Web of Science ®Google Scholar
• Martin F, Taylor GP. Prospects for the management of human T-cell lymphotropic virus type 1-associated myelopathy. AIDS Rev 2011;13(3):161-70
   PubMed Web of Science ®Google Scholar
• Machuca A, Rodes B, Soriano V. The effect of antiretroviral therapy on HTLV infection. Virus Res 2001;78(1-2):93-100
   PubMed Web of Science ®Google Scholar
• Nakagawa M, Nakahara K, Maruyama Y, et al. Therapeutic trials in 200 patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. J Neurovirol 1996;2(5):345-55
   PubMed Web of Science ®Google Scholar
• Croda MG, de Oliveira AC, Vergara MP, et al. Corticosteroid therapy in TSP/HAM patients: the results from a 10 years open cohort. J Neurol Sci 2008;269(1-2):133-7
   PubMed Web of Science ®Google Scholar
• Ahmed S, Adonis A, Hilburn S, et al. Treatment of patients with HTLV-1-associated myelopathy with methotrexate. 16th International Conference on Human Retroviruses: HTLV and Related Viruses, 2013 Retrovirology. Montreal, Canada: Retrovirology; 2014
   Google Scholar
• Martin F, Castro H, Gabriel C, et al. Cyclosporin A proof of concept study in patients with active, progressive HTLV-1 associated myelopathy/tropical spastic paraparesis. PLoS Negl Trop Dis 2012;6(6):e1675
   Web of Science ®Google Scholar
• Lehky TJ, Levin MC, Kubota R, et al. Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac. Ann Neurol 1998;44(6):942-7
   PubMed Web of Science ®Google Scholar
• Izumo S, Goto I, Itoyama Y, et al. Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-blind, controlled trial. Neurology 1996;46(4):1016-21
   PubMed Web of Science ®Google Scholar
• Lezin A, Gillet N, Olindo S, et al. Histone deacetylase mediated transcriptional activation reduces proviral loads in HTLV-1 associated myelopathy/tropical spastic paraparesis patients. Blood 2007;110(10):3722-8
   PubMed Web of Science ®Google Scholar
• Olindo S, Belrose G, Gillet N, et al. Safety of long-term treatment of HAM/TSP patients with valproic acid. Blood 2011;118(24):6306-9
   PubMed Web of Science ®Google Scholar
• Sheremata WA, Benedict D, Squilacote DC, et al. High-dose zidovudine induction in HTLV-I-associated myelopathy: safety and possible efficacy. Neurology 1993;43(10):2125-9
   PubMed Web of Science ®Google Scholar
• Taylor GP, Goon P, Furukawa Y, et al. Zidovudine plus lamivudine in human T-lymphotropic virus type-I-associated myelopathy: a randomised trial. Retrovirology 2006;3:63
   PubMed Web of Science ®Google Scholar
• Macchi B, Balestrieri E, Ascolani A, et al. Susceptibility of primary HTLV-1 isolates from patients with HTLV-1-associated myelopathy to reverse transcriptase inhibitors. Viruses 2011;3(5):469-83
   PubMed Web of Science ®Google Scholar
• Taylor GP, Hall SE, Navarrete S, et al. Effect of lamivudine on human T-cell leukemia virus type 1 (HTLV-1) DNA copy number, T-cell phenotype, and anti-tax cytotoxic T-cell frequency in patients with HTLV-1-associated myelopathy. J Virol 1999;73(12):10289-95
   PubMed Web of Science ®Google Scholar
• Hill SA, Lloyd PA, McDonald S, et al. Susceptibility of human T cell leukemia virus type I to nucleoside reverse transcriptase inhibitors. J Infect Dis 2003;188(3):424-7
   PubMed Web of Science ®Google Scholar
• Seegulam ME, Ratner L. Integrase inhibitors effective against human T-cell leukemia virus type 1. Antimicrob Agents Chemother 2011;55(5):2011-17
   PubMed Web of Science ®Google Scholar
• Trevino A, Parra P, Bar-Magen T, et al. Antiviral effect of raltegravir on HTLV-1 carriers. J Antimicrob Chemother 2012;67(1):218-21
   PubMed Web of Science ®Google Scholar
• Oh U, Yamano Y, Mora CA, et al. Interferon-beta1a therapy in human T-lymphotropic virus type I-associated neurologic disease. Ann Neurol 2005;57(4):526-34
   PubMed Web of Science ®Google Scholar
• Duncan J, Rudge P. Methylprednisolone therapy in tropical spastic paraparesis. J Neurol Neurosurg Psychiatry 1990;53(2):173-4
   PubMed Web of Science ®Google Scholar
• Ericson-Neilsen W, Kaye AD. Steroids: pharmacology, complications, and practice delivery issues. Ochsner J 2014;14(2):203-7
   PubMedGoogle Scholar
• Mochizuki M, Watanabe T, Yamaguchi K, et al. HTLV-I uveitis: a distinct clinical entity caused by HTLV-I. Jpn J Cancer Res 1992;83(3):236-9
   PubMedGoogle Scholar
• Miyanaga M, Shimizu K, Kawaguchi T, et al. A clinical survey of uveitis in HTLV-1 endemic region. Ocul Immunol Inflamm 2009;17(5):335-41
   PubMed Web of Science ®Google Scholar
• Pinheiro SR, Carneiro-Proietti AB, Lima-Martins MV, et al. HTLV-I/II seroprevalence in 55 Brazilian patients with idiopathic uveitis. Rev Soc Bras Med Trop 1996;29(4):383-4
   PubMedGoogle Scholar
• Merle H, Smadja D, Le Hoang P, et al. Ocular manifestations in patients with HTLV-I associated infection–a clinical study of 93 cases. Jpn J Ophthalmol 1996;40(2):260-70
   PubMed Web of Science ®Google Scholar
• Ono A, Ikeda E, Mochizuki M, et al. Provirus load in patients with human T-cell leukemia virus type 1 uveitis correlates with precedent Graves’ disease and disease activities. Jpn J Cancer Res 1998;89(6):608-14
   PubMedGoogle Scholar
• Kawai H, Yokoi K, Akaike M, et al. Graves’ disease in HTLV-I carriers. J Mol Med (Berl) 1995;73(2):85-8
   PubMed Web of Science ®Google Scholar
• Streho M, Delair E, Abad S, et al. [Uveitis associated with thyroiditis in HTLV-1 carriers]. Rev Med Internet 2005;26(11):894-6
   PubMed Web of Science ®Google Scholar
• Kihara K, Tsuruda M, Ono A, et al. [Human T-lymphotropic virus type 1 uveitis in children]. Nihon Ganka Gakkai Zasshi 1997;101(6):538-43
   PubMedGoogle Scholar
• Yoshimura K, Mochizuki M, Araki S, et al. Clinical and immunologic features of human T-cell lymphotropic virus type I uveitis. Am J Ophthalmol 1993;116(2):156-63
   PubMed Web of Science ®Google Scholar
• Mochizuki M, Watanabe T, Yamaguchi K, et al. Uveitis associated with human T-cell lymphotropic virus type I. Am J Ophthalmol 1992;114(2):123-9
   PubMed Web of Science ®Google Scholar
• Ono A, Mochizuki M, Yamaguchi K, et al. Immunologic and virologic characterization of the primary infiltrating cells in the aqueous humor of human T-cell leukemia virus type-1 uveitis. Accumulation of the human T-cell leukemia virus type-1-infected cells and constitutive expression of viral and interleukin-6 messenger ribonucleic acids. Invest Ophthalmol Vis Sci 1997;38(3):676-89
   PubMed Web of Science ®Google Scholar
• Cartier L, Castillo JL, Cea JG, Villagra R. Chronic dacryosialadenitis in HTLV I associated myelopathy. J Neurol Neurosurg Psychiatry 1995;58(2):244-6
   PubMed Web of Science ®Google Scholar
• Vitali C. Immunopathologic differences of Sjogren’s syndrome versus sicca syndrome in HCV and HIV infection. Arthritis Res Ther 2011;13(4):233
   PubMed Web of Science ®Google Scholar
• Brito-Zeron P, Ramos-Casals M. Advances in the understanding and treatment of systemic complications in Sjogren’s syndrome. Curr Opin Rheumatol 2014;26(5):520-7
   PubMed Web of Science ®Google Scholar
• Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61(6):554-8
   PubMed Web of Science ®Google Scholar
• Talal N, Dauphinee MJ, Dang H, et al. Detection of serum antibodies to retroviral proteins in patients with primary Sjogren’s syndrome (autoimmune exocrinopathy). Arthritis Rheum 1990;33(6):774-81
   PubMed Web of Science ®Google Scholar
• Green JE, Hinrichs SH, Vogel J, Jay G. Exocrinopathy resembling Sjogren’s syndrome in HTLV-1 tax transgenic mice. Nature 1989;341(6237):72-4
   PubMed Web of Science ®Google Scholar
• Eguchi K, Matsuoka N, Ida H, et al. Primary Sjogren’s syndrome with antibodies to HTLV-I: clinical and laboratory features. Ann Rheum Dis 1992;51(6):769-76
   PubMed Web of Science ®Google Scholar
• Terada K, Katamine S, Eguchi K, et al. Prevalence of Serum and Salivary Antibodies to Htlv-1 in Sjogren’s syndrome. Lancet 1994;344(8930):1116-19
   PubMed Web of Science ®Google Scholar
• Hida A, Kawabe Y, Kawakami A, et al. HTLV-I associated Sjogren’s syndrome is aetiologically distinct from anti-centromere antibodies positive Sjogren’s syndrome. Ann Rheum Dis 1999;58(5):320-2
   PubMed Web of Science ®Google Scholar
• Kawai H, Inui T, Kashiwagi S, et al. HTLV-I infection in patients with autoimmune thyroiditis (Hashimoto’s thyroiditis). J Med Virol 1992;38(2):138-41
   PubMed Web of Science ®Google Scholar
• Mizokami T, Okamura K, Ikenoue H, et al. A high prevalence of human T-lymphotropic virus type I carriers in patients with antithyroid antibodies. Thyroid 1994;4(4):415-19
   PubMed Web of Science ®Google Scholar
• Mine H, Kawai H, Yokoi K, et al. High frequencies of human T-lymphotropic virus type I (HTLV-I) infection and presence of HTLV-II proviral DNA in blood donors with anti-thyroid antibodies. J Mol Med (Berl) 1996;74(8):471-7
   PubMed Web of Science ®Google Scholar
• Kubonishi I, Kubota T, Sawada T, et al. An HTLV-I carrier with Graves’ disease followed by uveitis: isolation of HTLV-I from thyroid tissue. Int J Hematol 1997;66(2):233-7
   PubMed Web of Science ®Google Scholar
• Kawai H, Kashiwagi S, Sano Y, et al. [HTLV-I associated myelopathy with Hashimoto’s thyroiditis–a report of two cases]. Rinsho Shinkeigaku 1991;31(6):648-52
   PubMedGoogle Scholar
• Kawai H, Mitsui T, Yokoi K, et al. Evidence of HTLV-I in thyroid tissue in an HTLV-I carrier with Hashimoto’s thyroiditis. J Mol Med (Berl) 1996;74(5):275-8
   PubMed Web of Science ®Google Scholar
• Matsuda T, Tomita M, Uchihara JN, et al. Human T cell leukemia virus type I-infected patients with Hashimoto’s thyroiditis and Graves’ disease. J Clin Endocrinol Metab 2005;90(10):5704-10
   PubMed Web of Science ®Google Scholar
• Matsuyama W, Kawabata M, Mizoguchi A, et al. Influence of human T lymphotrophic virus type I on cryptogenic fibrosing alveolitis - HTLV-I associated fibrosing alveolitis: proposal of a new clinical entity. Clin Exp Immunol 2003;133(3):397-403
   PubMed Web of Science ®Google Scholar
• Yamashiro T, Kamiya H, Miyara T, et al. CT scans of the chest in carriers of human T-cell lymphotropic virus type 1: presence of interstitial pneumonia. Acad Radiol 2012;19(8):952-7
   PubMed Web of Science ®Google Scholar
• Steinfort DP, Brady S, Weisinger HS, Einsiedel L. Bronchiectasis in Central Australia: a young face to an old disease. Respir Med 2008;102(4):574-8
   PubMed Web of Science ®Google Scholar
• Einsiedel L, Fernandes L, Spelman T, et al. bronchiectasis is associated with human T-lymphotropic virus 1 infection in an indigenous Australian population. Clin Infect Dis 2012;54(1):43-50
   PubMed Web of Science ®Google Scholar
• Webb K, Hlela C, Scott C, et al. Infective dermatitis associated with human T-cell lymphotropic virus type 1 in a child with bronchiectasis. Pediatr Infect Dis J 2013;32(6):690-3
   PubMed Web of Science ®Google Scholar
• Sugimoto M, Mita S, Tokunaga M, et al. Pulmonary involvement in human T-cell lymphotropic virus type-I uveitis: T-lymphocytosis and high proviral DNA load in bronchoalveolar lavage fluid. Eur Respir J 1993;6(7):938-43
   PubMed Web of Science ®Google Scholar
• Sugimoto M, Nakashima H, Matsumoto M, et al. [T-lymphocytosis and increased levels of soluble IL-2 receptors in bronchoalveolar lavage fluid in cases of HTLV-I-associated myelopathy with pulmonary involvement]. Nihon Kyobu Shikkan Gakkai Zasshi 1989;27(4):481-7
   PubMedGoogle Scholar
• Seki M, Kadota JI, Higashiyama Y, et al. Elevated levels of beta-chemokines in bronchoalveolar lavage fluid (BALF) of individuals infected with human T lymphotropic virus type-1 (HTLV-1). Clin Exp Immunol 1999;118(3):417-22
   PubMed Web of Science ®Google Scholar
• Seki M, Higashiyama Y, Kadota J, et al. Elevated levels of soluble adhesion molecules in sera and BAL fluid of individuals infected with human T-cell lymphotropic virus type 1. Chest 2000;118(6):1754-61
   PubMed Web of Science ®Google Scholar
• Leung K, Nabel GJ. Htlv-1 Transactivator Induces Interleukin-2 Receptor Expression through an NF-Kappa-B-Like Factor. Nature 1988;333(6175):776-8
   PubMed Web of Science ®Google Scholar
• Tendler CL, Greenberg SJ, Blattner WA, et al. Transactivation of Interleukin-2 and Its Receptor Induces Immune Activation in Human T-Cell Lymphotropic Virus Type-I-Associated Myelopathy - Pathogenic Implications and a Rationale for Immunotherapy. P Natl Acad Sci USA 1990;87(13):5218-22
   PubMed Web of Science ®Google Scholar
• Higashiyama Y, Katamine S, Kohno S, et al. Expression of human T lymphotropic virus type 1 (HTLV-1) tax/rex gene in fresh bronchoalveolar lavage cells of HTLV-1-infected individuals. Clin Exp Immunol 1994;96(2):193-201
   PubMed Web of Science ®Google Scholar
• Nakayama Y, Yamazato Y, Tamayose M, et al. Increased expression of HBZ and Foxp3 mRNA in bronchoalveolar lavage cells taken from human T-lymphotropic virus type 1-associated lung disorder patients. Intern Med 2013;52(23):2599-609
   PubMed Web of Science ®Google Scholar
• Kawabata T, Higashimoto I, Takashima H, et al. Human T-lymphotropic virus type I (HTLV-I)-specific CD8+cells accumulate in the lungs of patients infected with HTLV-I with pulmonary involvement. J Med Virol 2012;84(7):1120-7
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Saijo Y, Sakai T, et al. Human T-cell lymphotropic virus type I (HTLV-I) carrier with clinical manifestations characteristic of diffuse panbronchiolitis. Intern Med 1996;35(4):305-9
   PubMed Web of Science ®Google Scholar
• Sweet RD. A pattern of eczema in Jamaica. Br J Dermatol 1966;78(2):93-100
   PubMed Web of Science ®Google Scholar
• LaGrenade L, Sonoda S, Miller W, et al. HLA DRB1*DQB1* haplotype in HTLV-I-associated familial infective dermatitis may predict development of HTLV-I-associated myelopathy/tropical spastic paraparesis. Am J Med Genet 1996;61(1):37-41
   PubMed Web of Science ®Google Scholar
• Hlela C, Graham N, Bhigjee AI, et al. Human T cell lymphotropic virus type 1- associated infective dermatitis in KwaZulu Natal, South Africa. BMC Dermatol 2013;13:11
   PubMedGoogle Scholar
• Bittencourt AL, Primo J, Oliveira MF. Manifestations of the human T-cell lymphotropic virus type I infection in childhood and adolescence. J Pediatr (Rio J) 2006;82(6):411-20
   PubMedGoogle Scholar
• Bittencourt AL, Oliveira Mde F, Brites C, et al. Histopathological and immunohistochemical studies of infective dermatitis associated with HTLV-I. Eur J Dermatol 2005;15(1):26-30
   PubMed Web of Science ®Google Scholar
• Ozden S, Mouly V, Prevost MC, et al. Muscle wasting induced by HTLV-1 tax-1 protein: an in vitro and in vivo study. Am J Pathol 2005;167(6):1609-19
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Understanding the immunopathogenesis of inclusion-body myositis: present and future prospects. Rev Neurol (Paris) 2002;158(10 Pt 1):948-58
   PubMed Web of Science ®Google Scholar
• Ferreira AS, Costa CM, Dantas IK, et al. Polymyositis in childhood as clinical manifestation associated with HTLV-1. Arq Neuropsiquiatr 2010;68(6):962-4
   PubMed Web of Science ®Google Scholar
• Masson C, Chaunu MP, Henin D, et al. [Myelopathy, polymyositis and systemic manifestations associated with the HTLV-I virus]. Rev Neurol (Paris) 1989;145(12):838-41
   PubMed Web of Science ®Google Scholar
• Morgan OS, Rodgers-Johnson P, Mora C, Char G. HTLV-1 and polymyositis in Jamaica. Lancet 1989;2(8673):1184-7
   PubMed Web of Science ®Google Scholar
• Gilbert DT, Morgan O, Smikle MF, et al. HTLV-1 associated polymyositis in Jamaica. Acta Neurol Scand 2001;104(2):101-4
   PubMed Web of Science ®Google Scholar
• Gabbai AA, Wiley CA, Oliveira AS, et al. Skeletal muscle involvement in tropical spastic paraparesis/HTLV-1-associated myelopathy. Muscle Nerve 1994;17(8):923-30
   PubMed Web of Science ®Google Scholar
• Leon-Monzon M, Illa I, Dalakas MC. Polymyositis in patients infected with human T-cell leukemia virus type I: the role of the virus in the cause of the disease. Ann Neurol 1994;36(4):643-9
   PubMed Web of Science ®Google Scholar
• Higuchi I, Montemayor ES, Izumo S, et al. Immunohistochemical characteristics of polymyositis in patients with HTLV-I-associated myelopathy and HTLV-I carriers. Muscle Nerve 1993;16(5):472-6
   PubMed Web of Science ®Google Scholar
• Desdouits M, Cassar O, Maisonobe T, et al. HTLV-1-associated inflammatory myopathies: low proviral load and moderate inflammation in 13 patients from West Indies and West Africa. J Clin Virol 2013;57(1):70-6
   PubMed Web of Science ®Google Scholar
• Cupler EJ, Leon-Monzon M, Miller J, et al. Inclusion body myositis in HIV-1 and HTLV-1 infected patients. Brain 1996;119(Pt 6):1887-93
   PubMed Web of Science ®Google Scholar
• Ozden S, Cochet M, Mikol J, et al. Direct evidence for a chronic CD8+-T-cell-mediated immune reaction to tax within the muscle of a human T-cell leukemia/lymphoma virus type 1-infected patient with sporadic inclusion body myositis. J Virol 2004;78(19):10320-7
   PubMed Web of Science ®Google Scholar
• Matsuura E, Umehara F, Nose H, et al. Inclusion body myositis associated with human T-lymphotropic virus-type I infection: eleven patients from an endemic area in Japan. J Neuropathol Exp Neurol 2008;67(1):41-9
   PubMed Web of Science ®Google Scholar
• Haynes BF, Miller SE, Palker TJ, et al. Identification of human T cell leukemia virus in a Japanese patient with adult T cell leukemia and cutaneous lymphomatous vasculitis. P Natl Acad Sci USA 1983;80(7):2054-8
   PubMed Web of Science ®Google Scholar
• Taniguchi A, Takenaka Y, Noda Y, et al. Adult T cell leukemia presenting with proliferative synovitis. Arthritis Rheum 1988;31(8):1076-7
   PubMed Web of Science ®Google Scholar
• Kitajima I, Maruyama I, Maruyama Y, et al. Polyarthritis in human T lymphotropic virus type I-associated myelopathy. Arthritis Rheum 1989;32(10):1342-4
   PubMed Web of Science ®Google Scholar
• Nishioka K, Maruyama I, Sato K, et al. Chronic inflammatory arthropathy associated with HTLV-I. Lancet 1989;1(8635):441
   PubMed Web of Science ®Google Scholar
• Motokawa S, Hasunuma T, Tajima K, et al. High prevalence of arthropathy in HTLV-I carriers on a Japanese island. Ann Rheum Dis 1996;55(3):193-5
   PubMed Web of Science ®Google Scholar
• Eguchi K, Origuchi T, Takashima H, et al. High seroprevalence of anti-HTLV-I antibody in rheumatoid arthritis. Arthritis Rheum 1996;39(3):463-6
   PubMed Web of Science ®Google Scholar
• Murphy EL, Wang B, Sacher RA, et al. Respiratory and urinary tract infections, arthritis, and asthma associated with HTLV-I and HTLV-II infection. Emerg Infect Dis 2004;10(1):109-16
   PubMed Web of Science ®Google Scholar
• Sebastian D, Nayiager S, York DY, Mody GM. Lack of association of Human T-cell lymphotrophic virus type 1(HTLV-1) infection and rheumatoid arthritis in an endemic area. Clin Rheumatol 2003;22(1):30-2
   PubMed Web of Science ®Google Scholar
• McCallum RM, Patel DD, Moore JO, Haynes BF. Arthritis syndromes associated with human T cell lymphotropic virus type I infection. Med Clin North Am 1997;81(1):261-76
   PubMed Web of Science ®Google Scholar
• Hasunuma T, Sumida T, Nishioka K. Human T cell leukemia virus type-I and rheumatoid arthritis. Int Rev Immunol 1998;17(5-6):291-307
   PubMedGoogle Scholar
• Sato K, Maruyama I, Maruyama Y, et al. Arthritis in Patients Infected with Human Lymphotropic-T Virus Type-I - Clinical and Immunopathologic Features. Arthritis Rheum 1991;34(6):714-21
   PubMed Web of Science ®Google Scholar
• Hasunuma T, Nishioka K, Nishioka K. Microorganisms in chronic arthritis. Lancet 1997;350(9071):145
   PubMed Web of Science ®Google Scholar
• Nakajima T, Aono H, Hasunuma T, et al. Overgrowth of human synovial cells driven by the human T cell leukemia virus type I tax gene. J Clin Invest 1993;92(1):186-93
   PubMed Web of Science ®Google Scholar
• Yakova M, Lezin A, Dantin F, et al. Increased proviral load in HTLV-1-infected patients with rheumatoid arthritis or connective tissue disease. Retrovirology 2005;2:4
   PubMed Web of Science ®Google Scholar
• Cush JJ, Lipsky PE. Phenotypic analysis of synovial tissue and peripheral blood lymphocytes isolated from patients with rheumatoid arthritis. Arthritis Rheum 1988;31(10):1230-8
   PubMed Web of Science ®Google Scholar
• Cush JJ, Pietschmann P, Oppenheimer-Marks N, Lipsky PE. The intrinsic migratory capacity of memory T cells contributes to their accumulation in rheumatoid synovium. Arthritis Rheum 1992;35(12):1434-44
   PubMed Web of Science ®Google Scholar
• Sakai M, Eguchi K, Terada K, et al. Infection of human synovial cells by human T cell lymphotropic virus type I. Proliferation and granulocyte/macrophage colony-stimulating factor production by synovial cells. J Clin Invest 1993;92(4):1957-66
   PubMed Web of Science ®Google Scholar
• Iwakura Y, Tosu M, Yoshida E, et al. Induction of inflammatory arthropathy resembling rheumatoid arthritis in mice transgenic for HTLV-I. Science 1991;253(5023):1026-8
   PubMed Web of Science ®Google Scholar
• Iwakura Y, Saijo S, Kioka Y, et al. Autoimmunity induction by human T cell leukemia virus type 1 in transgenic mice that develop chronic inflammatory arthropathy resembling rheumatoid arthritis in humans. J Immunol 1995;155(3):1588-98
   PubMed Web of Science ®Google Scholar
• Umekita K, Umeki K, Miyauchi S, et al. Use of anti-tumor necrosis factor biologics in the treatment of rheumatoid arthritis does not change human T-lymphotropic virus type 1 markers: a case series. Mod Rheumatol 2013. [Epub ahead of print]
   Web of Science ®Google Scholar
• Umekita K, Hidaka T, Miyauchi S, et al. Treatment with anti-tumor necrosis factor biologics in human T-lymphotropic virus type 1 positive patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013
   Web of Science ®Google Scholar
• Frenzel L, Moura B, Marcais A, et al. HTLV-1-associated arthropathy treated with anti-TNF-alpha agent. Joint Bone Spine 2014;81(4):360-1
   PubMed Web of Science ®Google Scholar
• Bowness P, Davies KA, Tosswill J, et al. Autoimmune disease and HTLV-1 infection. Br J Rheumatol 1991;30(2):141-3
   PubMedGoogle Scholar
• Murphy EL Jr, De Ceulaer K, Williams W, et al. Lack of relation between human T-lymphotropic virus type I infection and systemic lupus erythematosus in Jamaica, West Indies. J Acquir Immune Defic Syndr 1988;1(1):18-22
   PubMed Web of Science ®Google Scholar
• Akimoto M, Matsushita K, Suruga Y, et al. Clinical manifestations of human T lymphotropic virus type I-infected patients with systemic lupus erythematosus. J Rheumatol 2007;34(9):1841-8
   PubMed Web of Science ®Google Scholar
• Nagami S, Konisi T, Kataoka H, et al. [A case with HTLV-I associated myelopathy (HAM) accompanied by primary biliary cirrhosis (PBC) and autoimmune hepatitis (AIH)]. Rinsho Shinkeigaku 1999;39(11):1132-4
   PubMedGoogle Scholar
• Boschi-Pinto C, Stuver S, Okayama A, et al. A follow-up study of morbidity and mortality associated with hepatitis C virus infection and its interaction with human T lymphotropic virus type I in Miyazaki, Japan. J Infect Dis 2000;181(1):35-41
   PubMed Web of Science ®Google Scholar
• Okayama A, Maruyama T, Tachibana N, et al. Increased prevalence of HTLV-I infection in patients with hepatocellular carcinoma associated with hepatitis C virus. Jpn J Cancer Res 1995;86(1):1-4
   PubMedGoogle Scholar
• Miyazaki K, Yamaguchi K, Tohya T, et al. Human T-cell leukemia virus type I infection as an oncogenic and prognostic risk factor in cervical and vaginal carcinoma. Obstet Gynecol 1991;77(1):107-10
   PubMed Web of Science ®Google Scholar
• Demontis MA, Hilburn S, Taylor GP. Human T cell lymphotropic virus type 1 viral load variability and long-term trends in asymptomatic carriers and in patients with human T cell lymphotropic virus type 1-related diseases. AIDS Res Hum Retroviruses 2013;29(2):359-64
   PubMed Web of Science ®Google Scholar
• Yamano Y, Araya N, Sato T, et al. Abnormally high levels of virus-infected IFN-gamma+ CCR4+ CD4+ CD25+ T cells in a retrovirus-associated neuroinflammatory disorder. PLoS One 2009;4(8):e6517
   Web of Science ®Google Scholar
• Kagdi H, Melamed A, Hilburn S, et al. CD25+CCR4+ cells as a marker of HTLV-1-infected cells in peripheral blood. Retrovirology 2014;11(Suppl 1):139
   Google Scholar
• Oh J, Calabresi PA. Emerging injectable therapies for multiple sclerosis. Lancet Neurol 2013;12(11):1115-26
   PubMed Web of Science ®Google Scholar